173 related articles for article (PubMed ID: 19729180)
41. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.
Roden RB; Greenstone HL; Kirnbauer R; Booy FP; Jessie J; Lowy DR; Schiller JT
J Virol; 1996 Sep; 70(9):5875-83. PubMed ID: 8709207
[TBL] [Abstract][Full Text] [Related]
42. Expression of the bovine papillomavirus type 1, 2 and 4 L1 genes in the yeast Pichia pastoris.
Jesus AL; Mariz FC; Souza HM; Cordeiro MN; Coimbra EC; Leitão MC; Nascimento LM; Stocco RC; Beçak W; Freitas AC
Genet Mol Res; 2012 Aug; 11(3):2598-607. PubMed ID: 22869085
[TBL] [Abstract][Full Text] [Related]
43. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
44. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.
Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J
Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315
[TBL] [Abstract][Full Text] [Related]
45. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
46. Epidemiology of equine sarcoids in horses in western Canada.
Wobeser BK; Davies JL; Hill JE; Jackson ML; Kidney BA; Mayer MN; Townsend HG; Allen AL
Can Vet J; 2010 Oct; 51(10):1103-8. PubMed ID: 21197201
[TBL] [Abstract][Full Text] [Related]
47. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
48. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
49. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
50. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
51. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
52. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies.
Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB
Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565
[TBL] [Abstract][Full Text] [Related]
53. Saccharomyces cerevisiae is permissive for replication of bovine papillomavirus type 1.
Zhao KN; Frazer IH
J Virol; 2002 Dec; 76(23):12265-73. PubMed ID: 12414966
[TBL] [Abstract][Full Text] [Related]
54. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
55. In planta production of a candidate vaccine against bovine papillomavirus type 1.
Love AJ; Chapman SN; Matic S; Noris E; Lomonossoff GP; Taliansky M
Planta; 2012 Oct; 236(4):1305-13. PubMed ID: 22718313
[TBL] [Abstract][Full Text] [Related]
56. Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.
Ghim S; Christensen ND; Kreider JW; Jenson AB
Int J Cancer; 1991 Sep; 49(2):285-9. PubMed ID: 1715330
[TBL] [Abstract][Full Text] [Related]
57. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
58. L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.
Okun MM; Day PM; Greenstone HL; Booy FP; Lowy DR; Schiller JT; Roden RB
J Virol; 2001 May; 75(9):4332-42. PubMed ID: 11287582
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy of Equine Sarcoids-From Early Approaches to Innovative Vaccines.
Jindra C; Hainisch EK; Brandt S
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112681
[TBL] [Abstract][Full Text] [Related]
60. Optimization of multimeric human papillomavirus L2 vaccines.
Jagu S; Kwak K; Karanam B; Huh WK; Damotharan V; Chivukula SV; Roden RB
PLoS One; 2013; 8(1):e55538. PubMed ID: 23383218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
